江苏常铝铝业集团股份有限公司 2022 年第一季度报告全文 江苏常铝铝业集团股份有限公司 2022 年第一季度报告 2022 年 04 月 1 江苏常铝铝业集团股份有限公司 2022 年第一季度报告全文 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完 整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保 证季度报告中财务信息的真实、准确、完整。 3.第一季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增 | | --- | --- | --- | --- | | | | | 减 | | 营业收入（元） | 1,427,627,960.23 | 1,332,913,248.77 | 7.11% | | 归属于上市公司股东的净利润（元） | 23,765,225.53 | 28,174,126.67 | -15.65% | | 归属 ...

Financial Performance - The company's operating revenue for the first half of 2021 was CNY 2,931,152,231.13, representing a 71.16% increase compared to CNY 1,712,547,138.75 in the same period last year[20]. - The net profit attributable to shareholders of the listed company reached CNY 63,485,718.18, a significant turnaround from a loss of CNY 54,656,750.06, marking a 216.15% increase[20]. - The net cash flow from operating activities was CNY 12,467,467.92, up 434.38% from CNY 2,333,067.63 in the previous year[20]. - The basic earnings per share improved to CNY 0.0798 from a loss of CNY 0.0687, reflecting a 216.16% increase[20]. - The company reported a significant increase in net profit after deducting non-recurring gains and losses, reaching CNY 60,693,956.24, compared to a loss of CNY 58,989,351.18 last year, a 202.89% increase[20]. - The company's revenue for the reporting period reached ¥2,931,152,231.13, a 71.16% increase compared to ¥1,712,547,138.75 in the previous year, driven by rising aluminum prices and increased sales volume[35]. - The company's revenue for the industrial segment reached ¥2,734,204,327.60, representing a year-on-year increase of 62.58%[38]. - The medical clean segment saw a revenue increase of 442.66% year-on-year, attributed to improved order execution and previous pandemic-related delays[39]. - The company reported a significant increase in contract liabilities to ¥254,547,913.40, up from ¥168,779,181.38, reflecting increased advance payments for projects[41]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 6,997,755,846.58, an increase of 7.53% from CNY 6,507,582,475.31 at the end of the previous year[20]. - The net assets attributable to shareholders of the listed company increased to CNY 3,119,903,280.43, a rise of 2.17% from CNY 3,053,765,659.26[20]. - The company's total assets included cash of ¥709,063,153.00, which accounted for 10.13% of total assets, an increase from 8.24% at the end of the previous year[41]. - Inventory increased to ¥1,622,388,775.00, representing 23.18% of total assets, up from 20.66% the previous year[41]. - Short-term borrowings amounted to ¥1,617,289,096.00, which is 23.11% of total liabilities, a decrease from 24.12% the previous year[41]. - The total liabilities increased to CNY 3,878,377,327.31 as of June 30, 2021, compared to CNY 3,453,330,567.03 at the end of 2020, marking an increase of approximately 12.3%[123]. Cash Flow - The company's cash and cash equivalents increased by 110.40% to ¥78,590,180.21, reflecting the combined effects of operating, investing, and financing activities[35]. - Cash flow from operating activities was CNY 3,041,714,519.83, an increase from CNY 2,017,850,686.88 in the same period of 2020[137]. - The net cash flow from operating activities for the first half of 2021 was CNY 68,607,183.59, an increase of 93.5% compared to CNY 35,485,099.08 in the same period of 2020[142]. - Cash inflow from financing activities totaled CNY 1,512,460,071.09, compared to CNY 1,312,864,530.07 in the same period last year, indicating a 15.2% increase[139]. - Cash paid for debt repayment was CNY 1,265,278,436.06, compared to CNY 1,072,855,560.00 in the same period last year, reflecting a 17.9% increase[139]. Research and Development - Research and development expenses rose significantly to CNY 122,211,108.28 in the first half of 2021, up from CNY 52,478,406.32 in the same period of 2020, reflecting an increase of approximately 132.5%[128]. - Research and development expenses increased to CNY 67,703,794.71, up from CNY 37,239,078.06 in the first half of 2020, reflecting a focus on innovation[133]. - The company aims to expand its market presence and enhance product offerings through ongoing research and development initiatives[134]. Risk Management - The company has outlined potential risks and corresponding measures in its management discussion, emphasizing the importance of risk management strategies[6]. - The company faces risks related to rising raw material prices and cyclical fluctuations in the aluminum processing industry, which are sensitive to macroeconomic changes[52]. - Policy risks are present due to government regulations affecting the aluminum industry, which could impact the company's operational performance[53]. - Rising labor costs pose a challenge, necessitating improvements in efficiency and product value to maintain competitiveness[55]. Corporate Governance and Social Responsibility - The company is committed to sustainable development and enhancing its competitive edge through continuous innovation and talent development[33]. - Jiangsu Chang Aluminum Group is committed to social responsibility, ensuring fair treatment of shareholders and engaging in community support initiatives[65]. - The company emphasizes employee rights and well-being, implementing a comprehensive labor contract system and adhering to national labor laws, ensuring contributions to various insurance funds[66]. - The company actively participates in social welfare activities, contributing to poverty alleviation and educational support initiatives[68]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period is 66,259[106]. - The largest shareholder, Changshu Aluminum Foil Factory, holds 19.59% of the shares, with a decrease of 5,850,000 shares during the reporting period[106]. - The company commits to distribute cash dividends amounting to no less than 30% of the average distributable profit over the last three years from 2021 to 2023[74]. Compliance and Legal Matters - There are no significant litigation or arbitration matters during the reporting period[79]. - The company has not engaged in any violations regarding external guarantees during the reporting period[76]. - There were no penalties or rectifications during the reporting period, indicating a stable compliance status[81]. Accounting Policies - The company recognizes revenue when control of goods or services is transferred to customers, following specific accounting policies effective from January 1, 2020[168]. - The company adopts the Chinese accounting standards and reports its financials in Renminbi, while one subsidiary reports in USD[175]. - The financial statements reflect the company's financial position and performance as of June 30, 2021, in compliance with relevant accounting standards[171].

Financial Performance - The company's operating revenue for 2020 was ¥4,376,851,245.18, representing a 1.07% increase compared to ¥4,330,649,784.47 in 2019[19]. - The net profit attributable to shareholders for 2020 was ¥22,151,170.45, a 0.78% increase from ¥21,980,735.15 in 2019[19]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥1,220,142.89, a decrease of 108.86% compared to ¥13,768,323.22 in 2019[19]. - The net cash flow from operating activities decreased by 30.20% to ¥187,794,984.50 from ¥269,038,872.58 in 2019[19]. - Total assets at the end of 2020 were ¥6,507,582,475.31, an increase of 8.43% from ¥6,001,705,834.60 at the end of 2019[20]. - The net assets attributable to shareholders at the end of 2020 were ¥3,053,765,659.26, a 0.91% increase from ¥3,026,165,804.48 at the end of 2019[20]. - The company achieved a consolidated revenue of CNY 4.38 billion in 2020, representing a year-on-year growth of 1.07%[37]. - The net profit attributable to shareholders was CNY 22.15 million, an increase of 0.78% compared to the previous year[37]. - The cash flow from operating activities decreased by 30.20% year-on-year, amounting to CNY 187.80 million[37]. - The company reported a total revenue of 1.5 billion RMB for the year 2020, reflecting a year-on-year growth of 10%[92]. Dividend Policy - The company plans not to distribute cash dividends or issue bonus shares for the year[6]. - The company did not declare any cash dividends for 2020, 2019, or 2018, maintaining a cash dividend payout ratio of 0% for these years[88]. - The company has adhered to its cash dividend policy, which aligns with its articles of association and shareholder resolutions[84]. - The company has not proposed any capital reserve conversion into share capital for 2020 due to negative distributable profits[87]. Business Diversification and Strategy - The acquisition of Langmai Co. has diversified the company's operations into the pharmaceutical clean technology sector, reducing dependency on aluminum processing[5]. - The company’s main business has evolved to include pharmaceutical manufacturing and medical device production alongside aluminum products[17]. - The company is focusing on optimizing product structure and enhancing the value-added of materials through deep processing and innovation[29]. - The company is expanding its industrial layout with subsidiaries dedicated to raw material supply and further processing to meet customer demands in the air conditioning and automotive sectors[30]. - The company aims to enhance its market presence in new materials and products while ensuring operational stability amid market uncertainties[39]. - The company plans to adjust its product structure and strengthen its position in the industrial heat transfer sector while expanding into the automotive market[39]. - The company aims to enhance competitiveness and promote sustainable development through its dual business strategy of "Aluminum Processing + Health" moving forward[81]. Risk Management - The company reported a significant reliance on the aluminum rolling processing business, which is sensitive to macroeconomic changes and commodity price fluctuations[4]. - The company faces risks related to rising labor costs and the need for efficiency improvements through mechanization and standardization[5]. - The company’s overall risk management has improved due to the lower cyclical risks associated with the pharmaceutical industry[5]. Corporate Governance - The company’s financial report is guaranteed to be true, accurate, and complete by its management team[3]. - The company has established a comprehensive corporate governance structure and internal control system to ensure fair and transparent communication with all shareholders, enhancing transparency and credibility[124]. - The company has maintained compliance with decision-making procedures regarding dividend distribution and has ensured the protection of minority shareholders' rights[84]. - The company has no significant discrepancies with the regulatory requirements set by the China Securities Regulatory Commission regarding corporate governance[172]. Shareholder Information - The company has not reported any changes in its controlling shareholder since its listing[17]. - The company’s controlling shareholder, Changshu Aluminum Foil Factory Co., Ltd., has not undergone any changes during the reporting period[143]. - The largest shareholder, Changshu Aluminum Foil Factory Co., Ltd., holds 20.33% of the shares, totaling 161,742,997 shares, with a decrease of 2,371,492 shares during the reporting period[140]. - The company has a total of 78,931 shareholders at the end of the reporting period, with no changes in the structure of assets and liabilities reported[138]. Employee and Labor Relations - The total number of employees in the company is 2,243, with 1,536 in production, 117 in sales, 297 in technical roles, 95 in finance, and 198 in administration[164]. - The company has established a comprehensive training system for employees, including onboarding and ongoing training[167]. - The total compensation for directors and senior management during the reporting period amounts to 426.54 million yuan[164]. - The company has not implemented any employee incentive plans during the reporting period[104]. Audit and Compliance - The company received a standard unqualified audit report from the accounting firm for the 2020 financial statements[181]. - The audit committee held seven meetings during the reporting period, ensuring the legality and compliance of the company's fundraising and usage[180]. - There were no significant internal control deficiencies identified during the reporting period[186]. - The auditor evaluates the appropriateness of accounting policies and the reasonableness of accounting estimates and related disclosures made by management[200].

江苏常铝铝业集团股份有限公司 2020 年年度报告全文 江苏常铝铝业集团股份有限公司 （1）铝压延加工业务周期性波动的风险铝压延加工业务的下游行业主要是 建筑业、交通运输业和包装业等，属于周期性行业，对国家宏观经济的变化较 为敏感。此外，铝压延加工业务的上游为铝锭，属于大宗原材料，其价格受到 国际政治、经济、货币政策以及国内整体经济环境等因素的综合影响，波动较 大。未来，若宏观经济景气程度降低或大宗原材料市场的价格波动过大，都将 对公司铝压延加工业务未来的生产经营和盈利能力造成不利影响。 （2）政策风险近年来，铝压延加工业务方面，国家通过调整能源价格、限 制产能总量扩张、实施行业准入、优化结构、鼓励兼并重组等一系列政策手段 对铝行业实施宏观调控，支持行业内优势企业的可持续发展；医疗及医药健康 业务方面，近年来受到国家整体经济环境，医疗保障政策，医疗机构改革等宏 观政策的利好影响，行业取得了蓬勃发展，行业内企业的整体规模及产品技术 均有了大幅提升。因此，目前国内政策均对上市公司所处行业及行业内优势企 业的健康有序发展起到了良好的促进作用。未来，若相关业务受到政策调控的 2020 年年度报告 2021 年 04 ...

江苏常铝铝业集团股份有限公司 2021 年第一季度报告全文 江苏常铝铝业集团股份有限公司 2021 年第一季度报告 2021 年 04 月 1 江苏常铝铝业集团股份有限公司 2021 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人张平、主管会计工作负责人张伟利及会计机构负责人(会计主管 人员)易先付声明：保证季度报告中财务报表的真实、准确、完整。 2 江苏常铝铝业集团股份有限公司 2021 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入（元） | 1,332,913,248.77 | 805,513,004.26 | 65.47% | | 归属于上市公司股东的净利润（元） | 28,174,126.67 ...

江苏常铝铝业集团股份有限公司 2020 年第三季度报告全文 江苏常铝铝业集团股份有限公司 2020 年第三季度报告 2020 年 10 月 1 江苏常铝铝业集团股份有限公司 2020 年第三季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人张平、主管会计工作负责人张伟利及会计机构负责人(会计主管 人员)易先付声明：保证季度报告中财务报表的真实、准确、完整。 2 江苏常铝铝业集团股份有限公司 2020 年第三季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | --- | --- | --- | --- | --- | | 总资产（元） | 6,466,364,435.04 | | 6,001,705,834.60 | 7.74% | | 归属于上市公司股东的净资产 | 2,965 ...

Financial Performance - The company's operating revenue for the first half of 2020 was ¥1,712,547,138.75, a decrease of 21.08% compared to ¥2,170,071,715.39 in the same period last year[17]. - The net profit attributable to shareholders of the listed company was -¥54,656,750.06, representing a decline of 794.07% from ¥7,874,847.31 in the previous year[17]. - The net cash flow from operating activities was ¥2,333,067.63, down 67.61% from ¥7,203,911.45 in the same period last year[17]. - The company reported a basic earnings per share of -¥0.0687, a decrease of 760.58% from ¥0.0104 in the previous year[17]. - Net profit for the period was a loss of CNY 55.46 million, significantly down from the previous year, primarily due to the impact of the pandemic on the industry[34]. - The company reported a projected net profit loss of between -65 million to -65.4 million yuan for the first nine months of 2020, representing a decrease of 654.11% compared to the same period last year[68]. - The company experienced a significant decline in operating revenue and profit due to the adverse effects of the COVID-19 pandemic, with a recovery trend expected in the third quarter as industries restart[68]. Assets and Liabilities - The total assets at the end of the reporting period were ¥6,162,112,720.53, an increase of 2.67% from ¥6,001,705,834.60 at the end of the previous year[17]. - The net assets attributable to shareholders of the listed company decreased by 1.67% to ¥2,975,722,668.65 from ¥3,026,165,804.48 at the end of the previous year[17]. - Total liabilities increased to CNY 3,186,033,195.73 from CNY 2,975,200,571.09, which is an increase of approximately 7.09%[133]. - The company’s total equity attributable to shareholders was CNY 3,026,339,505.26 at the end of the reporting period[154]. Revenue Breakdown - Revenue from the industrial sector was ¥1,630,943,346.17, accounting for 95.23% of total revenue, down 18.16% from ¥1,992,780,177.22[39]. - Revenue from the medical clean sector dropped significantly by 64.81%, from ¥87,410,362.28 to ¥30,757,277.27, representing only 1.80% of total revenue[39]. - Revenue from other businesses decreased by 43.43%, from ¥89,881,175.89 to ¥50,846,515.31, accounting for 2.97% of total revenue[39]. - Revenue from mainland China was ¥1,345,523,325.11, down 18.07% from ¥1,642,299,118.83, representing 78.57% of total revenue[39]. - Revenue from countries outside mainland China decreased by 30.46%, from ¥527,772,596.56 to ¥367,023,813.64, accounting for 21.43% of total revenue[39]. Cash Flow and Investments - Cash and cash equivalents increased by 158.20% to CNY 373.52 million, attributed to a reduction in cash outflow from investment activities[38]. - The company’s monetary funds increased by 33.74% since the beginning of the year, mainly due to an increase in bank deposits[27]. - The cash flow from operating activities generated a net amount of CNY 2,333,067.63, significantly lower than CNY 7,203,911.45 in the previous year[149]. - The net cash flow from investing activities was CNY 9,252,485.79, compared to a negative CNY 119,869,843.95 in the previous year, indicating a significant improvement[152]. - The company reported a tax expense of CNY 62,596.19, compared to a tax benefit of CNY 243,701.99 in the first half of 2019[145]. Strategic Plans and Focus Areas - The company plans to optimize its product structure and enhance the value-added of materials through deep processing[25]. - The company is focusing on the automotive and air conditioning sectors within its thermal transmission business, collaborating with major partners like Valeo and Behr[25]. - The company plans to strengthen its market presence in the automotive and new energy sectors, particularly in heat exchange materials[34]. - The company is committed to enhancing its competitiveness and sustainable operations through innovation and transformation[25]. - The company plans to focus on expanding its market presence and investing in new technologies to drive future growth[134]. Shareholder and Equity Information - The total number of shares before the change was 795,581,976, with a decrease of 4,036,388 shares due to shareholder reductions[109]. - The largest shareholder, Changshu Aluminum Foil Factory, holds 22.76% of shares, totaling 181,072,897 shares[112]. - The company has not reported any changes in its board of directors or senior management during the reporting period[124]. - The company has not undergone any changes in its controlling shareholder during the reporting period[114]. Risk Management and Challenges - The company is facing risks related to the cyclical fluctuations of the aluminum processing business, which is sensitive to macroeconomic changes[69]. - The company plans to mitigate risks from rising labor costs by promoting technological upgrades and automation[71]. - The company has indicated that the competitive landscape in the pharmaceutical equipment sector has intensified, impacting profit margins[58]. Accounting and Financial Reporting - The financial statements are prepared in accordance with the accounting standards issued by the Ministry of Finance, ensuring a true and complete reflection of the company's financial status as of June 30, 2020[178]. - The company adopts the Chinese Yuan as its functional currency for accounting purposes[182]. - The company recognizes cash and cash equivalents in its cash flow statement, ensuring liquidity for operational needs[190]. - The company’s consolidated financial statements include all subsidiaries under its control, reflecting the overall financial condition and performance of the group[185].

Financial Performance - The company reported a net profit attributable to shareholders for 2019 was ¥21,980,735.15, a significant turnaround from a loss of ¥430,349,492.60 in 2018, representing a 105.11% increase[24]. - The company's operating revenue for 2019 was ¥4,330,649,784.47, an increase of 4.66% compared to 2018[24]. - The net cash flow from operating activities reached ¥269,038,872.58, marking a 367.26% increase from the previous year[24]. - The basic earnings per share for 2019 was ¥0.0287, compared to a loss of ¥0.59 per share in 2018, reflecting a 105.08% improvement[24]. - The company achieved a total revenue of CNY 4.33 billion in 2019, representing a year-on-year growth of 4.66%[43]. - The industrial segment contributed CNY 3.93 billion, accounting for 90.77% of total revenue, with a growth of 5.17% compared to 2018[52]. - The medical clean business generated CNY 399.87 million, which is a slight decrease of 0.09% year-on-year, representing 9.23% of total revenue[52]. - The gross profit margin for the industrial segment was 15.03%, while the medical clean segment had a gross profit margin of 19.31%[55]. - The company reported a net profit of CNY 21.98 million, successfully turning around from a loss in the previous year[43]. Business Strategy and Operations - The company reported a significant reliance on the aluminum rolling processing business, which is sensitive to macroeconomic changes and commodity price fluctuations[5]. - The acquisition of Langmai Co. has diversified the company's operations into the pharmaceutical clean technology sector, reducing dependency on aluminum processing[8]. - The company’s main business has evolved to include pharmaceutical manufacturing and medical device production alongside aluminum products[22]. - The company plans to focus on expanding market share, particularly in the alloy materials sector, and enhancing its presence in the automotive and new energy vehicle markets[45]. - The company aims to strengthen internal collaboration among subsidiaries to leverage the advantages of the entire industrial chain[48]. - The company is committed to maintaining stable operations while adjusting product structures and promoting industrial transformation and upgrading[49]. - The company is focusing on optimizing product structure and enhancing the value-added of materials, particularly in the automotive and air conditioning sectors[34]. Financial Management and Investments - The company plans to not distribute cash dividends or issue bonus shares for the year[10]. - The total amount of raised funds is 122,362,000 CNY, with 98,438,840 CNY already utilized, representing 80.5% of the total[79]. - The company has committed to invest 121,928,300 CNY in various projects, with 121,493,000 CNY already invested, achieving an investment progress of 99.64%[81]. - The company has successfully returned 50,000,000 CNY in bank loans, achieving 100% of the planned repayment[82]. - The company plans to invest RMB 180 million in the pharmaceutical equipment production project, with RMB 153.89 million sourced from raised funds[83]. - The company has incurred a cumulative change in the use of raised funds amounting to 14,781,030 CNY, which is 12.17% of the total raised funds[79]. Governance and Compliance - The company’s governance structure must align with its expanded business scope to mitigate cross-industry operational risks[8]. - The company has established a comprehensive corporate governance structure to protect the rights of shareholders and creditors[132]. - The company will strictly adhere to laws and regulations regarding related party transactions and will avoid any illegal occupation of the company's funds and assets[101]. - The company has made commitments to avoid any direct or indirect competition with its subsidiaries during the holding period of more than 5% of shares[101]. - The company has no significant accounting errors that require retrospective restatement during the reporting period[105]. - The company received a standard unqualified audit opinion from the accounting firm for the 2019 financial statements[197]. Market and Competition - The company faces risks from rising labor costs due to labor shortages in economically developed regions[9]. - The company has faced challenges in the production of key pharmaceutical equipment, which remains dominated by major competitors, limiting its EPC project expansion[83]. - The company plans to focus on expanding its market presence and enhancing product development in response to increasing competition in the pharmaceutical equipment sector[82]. Research and Development - The company has established a strong research and development platform, including a national-level enterprise technology center, to support product innovation and process optimization[39]. - Research and development expenses amounted to ¥140,339,494.10, reflecting an 8.77% increase from ¥129,022,482.61 in the previous year[64]. - The company is investing 200 million CNY in R&D for new technologies aimed at improving production efficiency by 25%[171]. Social Responsibility and Employee Welfare - The company actively engages in social responsibility, supporting community development and public welfare initiatives[131]. - The company emphasizes employee rights and welfare, implementing full labor contracts and providing various insurance benefits[133]. - The company has established a comprehensive training system for employees, including onboarding and ongoing training programs[183]. Shareholder Information - The company issued 38,985,505 new shares to raise funds for asset acquisition, resulting in a total share count of 795,581,900[145]. - The largest shareholder, Changshu Aluminum Foil Factory Co., Ltd., holds 23.31% of the shares, amounting to 185,457,926 shares[152]. - The company has a total of 43,219 common shareholders as of the end of the reporting period[151]. - The company is actively expanding its shareholder base through private placements to strategic investors[148].

Financial Performance - The company’s operating revenue for 2019 was ¥4,330,649,784.47, an increase of 4.66% compared to 2018[24]. - The net profit attributable to shareholders was ¥21,980,735.15, a significant turnaround from a loss of ¥430,349,492.60 in 2018, representing a 105.11% increase[24]. - The net cash flow from operating activities reached ¥269,038,872.58, marking a 367.26% increase from the previous year[24]. - The basic earnings per share for 2019 was ¥0.0287, compared to a loss of ¥0.59 per share in 2018, reflecting a 105.08% improvement[24]. - The company achieved a total revenue of CNY 4.33 billion in 2019, representing a year-on-year growth of 4.66%[43]. - The industrial segment contributed CNY 3.93 billion, accounting for 90.77% of total revenue, with a growth of 5.17% compared to 2018[52]. - The medical clean business generated CNY 399.87 million, representing 9.23% of total revenue, with a slight decline of 0.09% year-on-year[52]. Dividend Policy - The company plans to not distribute cash dividends or issue bonus shares for the year[10]. - The company reported a net profit of RMB 21,980,735.15 for the year 2019, with a negative distributable profit of RMB -163,725,989.12[88]. - The company will not distribute cash dividends or issue bonus shares for the year 2019 due to negative distributable profits[88]. - The company has not proposed any cash dividend distribution plans for the reporting period despite having positive profits available for distribution in the parent company[94]. - The cash dividend policy complies with the company's articles of association and shareholder resolutions, ensuring the protection of minority shareholders' rights[89]. Business Diversification - The acquisition of Langmai Co. has diversified the company's operations into the pharmaceutical clean technology sector, reducing dependency on aluminum processing[8]. - The company’s main business has evolved to include pharmaceutical manufacturing and medical device production alongside aluminum products[22]. - The company aims to develop a dual business strategy of "aluminum processing + health" to enhance competitiveness and promote sustainable development[85]. Operational Risks - The company reported a significant reliance on the aluminum rolling processing business, which is sensitive to macroeconomic changes and commodity price fluctuations[5]. - The company faces risks from rising labor costs due to labor shortages in economically developed regions[9]. - The company’s overall financial performance is subject to potential negative impacts from macroeconomic downturns and policy adjustments[7]. Governance and Compliance - The company’s governance structure must align with its expanded business scope to mitigate cross-industry operational risks[8]. - The company’s financial advisor, Guojin Securities, has been engaged for continuous supervision since July 2014[23]. - The company has not faced any penalties or rectification issues during the reporting period[106]. - The company has no existing self-operated or jointly operated businesses that directly or indirectly compete with its listed company and subsidiaries[97]. Research and Development - Research and development expenses for 2019 amounted to ¥140.34 million, reflecting an 8.77% increase from the previous year, with R&D expenses constituting 3.24% of total revenue[63]. - The number of R&D personnel increased by 30.19% to 345, although their proportion of total employees slightly decreased[64]. Employee Welfare and Management - The company has committed to improving employee welfare, including providing medical and social insurance as well as enhancing work-life balance[129]. - The company has established a comprehensive training system, including onboarding and in-service training, to enhance employee skills and align with corporate culture[3]. - The total remuneration for directors, supervisors, and senior management during the reporting period amounted to 431,000 yuan[175]. Environmental and Social Responsibility - The company has maintained its ISO14001 environmental management system since 2006, focusing on comprehensive environmental protection measures[134]. - The company has actively participated in social welfare activities, contributing to various charitable causes[131]. - The company has made contributions to social welfare and supports vulnerable groups, promoting harmonious development with the community[127]. Shareholder Structure and Transactions - The largest shareholder, Changshu Aluminum Foil Factory, holds 185,457,926 shares, representing 23.31% of the total shares[149]. - The company has a total of 43,219 common shareholders as of the end of the reporting period[147]. - The company issued 38,985,505 new shares to raise funds for asset acquisition, resulting in a total share count of 795,581,900[140]. Internal Controls and Audit - The audit committee held seven meetings during the reporting period, ensuring compliance and accuracy in financial reporting[192]. - The internal control self-assessment report was disclosed on April 24, 2020, confirming effective internal controls related to financial statements[199]. - There were no significant internal control deficiencies identified during the reporting period[197].